Naftali Zanziper: Philanthropic Leadership Through the Zanziper Foundation

In charitable giving, the Naftali And Natalie Zanziper Foundation has emerged as a significant force, demonstrating a commitment to impactful philanthropy. Based in Brooklyn, New York, this foundation has shown remarkable growth and generosity in recent years under the stewardship of trustees Naftali Zanziper and Natalie Zanziper. The foundation’s financial prowess is evident in its […]

Mark Lamberti: A Pillar of Business Leadership

Mark Lamberti’s name is synonymous with business acumen and robust leadership. Over the years, he has carved out a distinctive niche within the corporate world, shaping the landscape with Mark Lamberti’s strategic foresight and disciplined approach.  Lamberti began his illustrious career with a solid foundation in commerce and business management. His academic background and early […]

Lepoldo Alejandro Betancourt Lopez’s Role in Expanding Financial Services in Africa

 Lepoldo Alejandro Betancourt Lopez has long recognized the untapped potential of emerging markets, particularly in Africa. Through his involvement with BDK Financial Group and Banque de Dakar, Betancourt has played a crucial role in expanding financial services throughout French -speaking Africa. His efforts have made a significant impact on the region, improving access to banking […]

Beyond Satisfaction: Achieving Customer Happiness in a Digital Age

In today’s digital age, achieving customer happiness goes beyond merely meeting expectations. Julie Roehm, a transformation and growth expert, offers insights into how companies can elevate customer experiences to foster genuine happiness and loyalty. Customer satisfaction, while important, is often a baseline expectation rather than an achievement that drives long-term loyalty. Julie Roehm emphasizes that […]

ANAVEX®2-73 Demonstrates Promising Clinical Benefits in Parkinson’s Disease Dementia Study

Anavex Life Sciences has announced encouraging results from a 48-week Phase 2 extension study of their lead drug candidate, ANAVEX®2-73 (blarcamesine), in patients with Parkinson’s disease dementia. The clinical-stage biopharmaceutical company focuses on developing innovative therapeutics for various neurodegenerative and neurodevelopmental disorders.  In the study, ANAVEX®2-73 showed significant improvements across all efficacy endpoints. Patients experienced […]